Table 2.
Characteristics of MSI-H tumors.
| EAC | GAC | SBAC | LBAC | PDAC | BDAC | |
|---|---|---|---|---|---|---|
| n (total) | 8 | 44 | 2 | 27 | 0 | 1 |
| UICC Stage | ||||||
| 1 | 0 | 13 | 0 | 7 | 0 | 0 |
| 2 | 2 | 10 | 0 | 10 | 0 | 0 |
| 3 | 5 | 13 | 3 | 5 | 0 | 0 |
| 4 | 1 | 3 | 0 | 5 | 0 | 1 |
| Gender | ||||||
| female | 2 | 14 | 0 | 15 | 0 | 0 |
| male | 6 | 25 | 2 | 12 | 0 | 1 |
| Age | ||||||
| >60 | 3 | 38 | 1 | 25 | 0 | 1 |
| <60 | 5 | 6 | 1 | 2 | 0 | 0 |
Compilation of tumor and patient characteristics with MSI-H (UICC tumor stages, gender and age distribution). EAC, esophageal adenocarcinoma; GAC, gastric adenocarcinoma; SBAC, small bowel adenocarcinoma; LBAC, large bowel adenocarcinoma; PDAC, pancreatic ductal adenocarcinoma; BDAC, bile duct adenocarcinoma.